Compare Marathon Petroleum Corp (MPC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs ResMed Inc. — how do they compare? Marathon Petroleum Corp trades at $466.62 (market cap $130.12B), while ResMed Inc. trades at $228.88 (market cap $31.89B). The key difference: Marathon Petroleum Corp is far larger — about 4.1× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and ResMed Inc. for 51 Days on average.
| MPC | RMD | |
|---|---|---|
Market Cap | $130.12B | $31.89B |
Volume | 2,749,647 | 618,314 |
Sector | Energy | Health |
52-Week High | $463.34 | $277.88 |
52-Week Low | $162.63 | $182.82 |
Typical Hold Time | 54 Days | 51 Days |
Enterprise Value | $156.64B | $31.24B |
Dividend Yield | 0.86% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $442.26, up 2.29% today, reflecting strong momentum amid bullish technical signals and recent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.07, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export restrictions and volatile energy markets.
Outlook remains positive with 75.8% of analysts rating it a buy and a consensus price target of $420.30. Key opportunities include elevated refining margins and solid cash flow, while risks involve regulatory uncertainty and cyclical demand pressures. The stock's valuation and growth prospects support a constructive view for investors seeking energy exposure.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
